Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs.
Additionally, KIND-510a targets non-regenerative anemia in cats, while an anti-TNF antibody is being developed for canine inflammatory bowel disease. Further candidates within its biologics portfolio are also under investigation. Established in 2012, Kindred Biosciences is headquartered in Burlingame, California.